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Introduction
Magnetic resonance imaging (MRI) is now used routinely
in the investigation of the pituitary gland, and is accepted
as the most sensitive imaging method for the diagnosis of
pituitary microadenomas.1 In symptomatic patients with
galactorrhoea, menstrual irregularities, amenorrhoea, or
impaired reproductive function, prolactin disorders
should be suspected and pituitary adenoma should be
sought. Reported sensitivities of MRI in the detection of
microadenomas vary widely, but are about 85-90% for
contrast-enhanced studies.2 The diagnosis of prolactin-
secreting pituitary adenoma is made on clinical and
endocrinological evidence. The role of radiology is to
assess the size of the adenoma (to assess the effects of
therapy), and possibly the feasibility of surgery. Though
computed tomography (CT) was thought to be extremely
useful in the diagnosis of pituitary microadenomas,3 high-
resolution MRI has become the most sensitive means for
their detection.4 Previous studies suggest a high rate of
detection.5
A study of 74 patients in 1996, with serum prolactin levels
above 52ng/ml found microadenomas in 38 (51.3%)
patients, macroadenomas in 6 (8.1%) and an infundibular
glioma in 1 (1.35%); 29 (39.18%) patients had a normal
pituitary gland.6
There is little published literature available in Pakistan
focussing on serum prolactin level and pituitary tumours.
The aim of the current study was to evaluate the MRI
findings of pituitary gland with reference to serum
prolactin level. 
Patients and Methods
The retrospective descriptive study was conducted at
the Department of Radiology, Aga Khan University
Hospital, Karachi, and comprised patients' data related
to a period from April 19, 2006 to April 23, 2009. During
the period, 70 patients had undergone MRI brain for
pituitary gland. Patients suspected on the basis of
clinical and biochemical findings of pituitary
abnormality were included, while those who were
claustrophobic or had a pacemaker or an intracerebral
aneurysm clip, metallic foreign body in the orbit or
with no laboratory investigation were excluded from
the study. 
Blood sampling was performed because of symptoms
such as sterility, galactorrhoea, amenorrhoea,
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Abstract
Objective: To explore equation, if any, between findings of magnetic resonance imaging of pituitary gland and
serum prolactin level. 
Methods: The retrospective, descriptive study was conducted at the Department of Radiology, Aga Khan University
Hospital, Karachi, and related to patients' records from April 19, 2006 to April 23, 2009. Seventy patients underwent
magnetic resonance imaging of brain for pituitary gland. Inclusion criteria were all patients referred with relevant
clinical symptoms or deranged serum prolactin level. Patients who were claustrophobic or had a pacemaker,
aneurysm clip, metallic foreign body in the orbit or with no laboratory investigation were excluded from the study.
SPSS 19 was used for statistical analysis.
Results: Of the 70 patients, normal imaging was noted in 29 (41.4 %) patients. Out of these, 18 (62.06%) patients had
normal and 11 (37.93%) had raised serum prolactin levels. Microadenoma was found in 23 (32.8%) patients. Out of
these, 10 (42.47%) had normal and 13 (56.52%) had raised prolactin levels. Macroadenoma was found in 16 (22.8 %).
Out of these, 8 (50%) had normal and 8 (50%) had raised prolactin levels. Pituitary cyst was located in 2 (2.8 %)
patients. Out of these, 1 (50%) had normal and 1 (50%) had raised serum prolactin levels.
Conclusion: Magnetic resonance imaging of pituitary gland was not associated with serum prolactin levels in
patients with clinical suspicion of pituitary abnormality. Therefore, regular monitoring of serum prolactin is
suggested.
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oligomenorrhoea, headache or visual loss. The normal
level of serum prolactin in males is 4.04 - 15.2ng/ml and in
females 4.79-23.3ng/ml. The method used for serum
prolactin level was Chemi-Luminescence.
MRI examinations were performed on a SIEMENS
AVANTO (1.5 Tesla) MRI scanner unit with the
following sequences: T1-weighted spin-echo (T1-SE;
TR 420, TE 15 ms), with 3mm contiguous coronal
slices; T2-weighted spin-echo (T2-SE; TR 3610, TE 111
ms), with 3mm contiguous coronal slices; and a
sagittal T1 acquisition. The field of view was 21cm and
the acquisition matrix 272x320. All patients were
initially examined without gadolinium (T1-SE)
followed by a 0.1mg/kg of gadolinium
diethylenetriaminepeutaacetic acid (DTPA), given
intravenously just before beginning the acquisition.
Dynamic study was also performed.
The study was considered positive if the pituitary gland
contained a focal area of low signal on unenhanced
images and/or less enhancement than the adjacent
gland on contrast-enhanced images.7 The size of the
tumour was measured on the hard copy sagittal and
coronal images. The maximum sagittal, transverse and
coronal diameters were recorded.8 The serum prolactin
level in patients with relevant clinical symptoms were
measured and MRI performed to locate pituitary
adenoma.
Based on size, an adenoma can be classified as a
microadenoma (a tumour less than 10mm in diameter)
or macroadenoma (a tumour more than 10mm in
diameter). Rathke's cleft cyst is a benign growth found
on the pituitary gland in the brain, specifically a fluid
filled cyst in the posterior portion of the anterior
pituitary gland. It occurs when the Rathke's pouch does
not develop properly and ranges in size from 2-40mm in
diameter. 
Since this was a retrospective observational study and all
information was obtained from medical records and
participants confidentiality was maintained, formal
approval from the Ethical Review Committee was not
taken.
Data was statistically analysed by SPSS version 19.0. A
descriptive analysis was done for demographic, clinical
and radiographic features and results were presented as
mean±standard deviation for quantitative variables and
frequency (percentage) for qualitative variables. Prolactin
level was categorised into two groups; normal and raised.
Frequency and percentages of MRI findings were
calculated accordingly.
Results
Out of the 70 patients, 8 (11.42%) were in-door patients,
15 (21.42%) were outside referrals and 47 (67.14%) were
referred from clinics at the centre. The total comprised 50
(71.42%) female patients and 20 (28.57%) were male with
age ranging from 3 to 75 years.
MRI revealed adenomas in 39 (55.7%) patients.
Microadenomas were found in 23 (32.8%). Out of these
10 (43.47%) had normal and 13 (56.52%) had raised
prolactin levels. Macroadenomas were found in 16
(22.8%); 8 (50%) had normal and 8 (50%) had raised
prolactin levels. In 2 (2.8%) patients, pituitary cyst was
found (size: 0.5x0.4cm in patient with serum prolactin
level of 26.6ng/ml, and 0.3x0.3cm in patient with serum
prolactin level of 5.17ng/ml). In 29 (41.4%) patients, MRI
was negative (Tables 1 and 2). The serum prolactin level
in patients with evidence of pituitary microadenoma
ranged from 0.7ng/ml to 207ng/ml. In patients with
macroadenomas, the level ranged from 0.21ng/ml to
595.7ng/ml. In patients with pituitary cyst, the level
ranged from 5.17-26.6ng/ml. The serum prolactin level
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Table-1: Serum prolactin level and MRI findings in pituitary gland.
MRI Findings Normal Prolactin High Prolactin
Normal (n = 29) 18(62%) 11(37.9%)
Macro Adenoma (n = 16) 8(50%) 8(50%)
Micro Adenoma (n = 23) 10(43.4%) 13(56.5%)
Cyst (n = 2) 1(50%) 1(50%)
MRI: Magnetic resonance imaging.
Table-3: MRI findings in pituitary gland in female patients with hyperprolactinaemia.
Serum Prolactin Level Normal Pituitary Gland Macro Adenoma Micro Adenoma Pituitary Cyst
High Prolactin (n=25) 8(32%) 6(24%) 10(40%) 1(4%)
MRI: Magnetic resonance imaging.
Table-2: MRI with normal and high prolactin level in cases of pituitary gland.
MRI Normal Prolactin High Prolactin
Normal 18(62%) 11(37.9%)
Abnormal 19(46.3%) 22(53.6%)
MRI: Magnetic resonance imaging.
of patients without evidence of adenoma ranged from
1.1ng/ml to 99.8ng/ml. Hyperprolactinaemia was
diagnosed in 32(45.7%) subjects. Out of these, 25
(78.1%) were females and 7 (21.8%) were males. The
mean age was 36.4±14.5 years in females (range: 21-75
years) and 43.5±16.4 years (range: 19-69 years) in males.
In 25 female patients, 10 (40%) were diagnosed as
pituitary microadenomas, 6(24%) were
macroadenomas, 8(32%) were normal, and 1(4%) case
was diagnosed as pituitary cyst (Table-3). In 7 male
patients, 3(42.8%) were diagnosed as pituitary
microadenomas, 1 (14.2%) was macroadenoma, and 3
(42.8%) cases were normal.
Discussion
Pituitary tumours are common neoplasms. Most of our
findings are in accordance with literature from the West.
Majority of the published literature is in international
journals. There is little published literature available in
local journals or from Pakistan with focus on serum
prolactin level and pituitary tumours.
Pituitary tumours constitute 10-15% of intracranial
tumours in surgical specimens.9 Prolactin-secreting
tumours are benign neoplasms that account for about
40% of all pituitary tumours. Over 90% are small,
intrasellar tumours that rarely increase in size.10 Patients
with pituitary tumours present with symptoms of a mass
lesion, endocrine dysfunction or both. Endocrine
dysfunction may be hyperfunction, hypofunction or
both. Prolactinomas are usually seen in clinical practice
earlier in females compared to the males; in the latter
these are usually macroadenomas.11 The earlier
presentation in females is because of the effects of
hyperprolactinaemia on gonadal function which is
observed early. Serum hormone assay and
stimulation/suppression tests are generally sufficient to
allow a confident clinical diagnosis of functioning
pituitary adenoma. In the low abnormal range (25-
200ng/ml), however, many other causes of
hyperprolactinaemia are possible, including drugs,
metabolic disturbances, chest wall lesions, tumours,
sarcoidosis and tuberculosis. It is, therefore, essential to
exclude an adenoma.7 Adenoma with a diameter of 3mm
seem to be the smallest diameter at which tumours of
adenohypophysis can be diagnosed with certainty as
microadenomas. Smaller lesions are critical in terms of
resolution and could only be vaguely suspected. A
previous study12 described a positive correlation
between tumour size and serum prolactin level. In a
larger series we did not find significant results when
correlating serum prolactin levels with tumour size. A
microadenoma usually gives lower signal than the
surrounding pituitary tissue, before and after contrast
medium. Microadenomas rarely enhance. Dynamic MRI
of the pituitary with a bolus injection of gadolinium13
demonstrates that adenomas enhance more slowly,
peaking later than the normal pituitary tissue.
Prolactinomas are relatively rare in males and more
than 70% of the cases occur in females.14 Women with
hyperprolactinaemia are usually detected early due to
classical presentation of amenorrhoea and
galactorrhoea and usually have a microadenoma. The
presentation of prolactinoma in males is usually
confusing;15 impotence and decreased libido are the
most frequent symptoms, but the diagnosis is only
made after the signs of compression due to tumour
pressure.16 Non-functioning pituitary tumours do not
produce any hormones but may cause a deficiency of
one or more pituitary hormones by crowding out
normal pituitary tissue or prolactin excess by causing
stalk compression. Of our subjects, 22.8% were
diagnosed to have non-functioning pituitary tumours.
Approximately 25-30% of patients are described to
have non-functioning pituitary tumours in the
literature.17
Some authors have reported a positive correlation
between tumour volume and serum prolactin value.18
This might be true for patients with
hyperprolactinaemia. However, when patients without
hyperprolactinaemia are also included as in the present
study, where some of the patients had normal serum
prolactin values, many of them with large tumours, no
such correlation is found.
A small sample size and being a single-centre study,
the current study does have its limitations. In
addition, the study shares the limitations of all
retrospective studies.
Conclusion
MRI pituitary findings were not associated with serum
prolactin levels in patients with clinical suspicion of
pituitary abnormality. Therefore, regular monitoring of
serum prolactin is suggested. Further large multi-centre
studies are suggested to establish the association.
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